SCHEMBL2179325

SCHEMBL2179325

CC(C)(C)OC(=O)c1ccc(CCCCCCCCCCCCC(=O)O)s1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 2/20 0.66
ALDH1A1 P00352 1/20 0.66
LMNA P02545 1/20 0.66
PRNP P04156 1/20 0.66
RECQL P46063 1/20 0.66
TDP1 Q9NUW8 2/20 0.63
POLB P06746 1/20 0.63
HPGD P15428 1/20 0.51
RXRA P19793 3/20 0.41
NR1H2 P55055 3/20 0.41
NR1H3 Q13133 1/20 0.41
MAPT P10636 2/20 0.40
PRSS1 P07477 3/20 0.37
TMPRSS15 P98073 3/20 0.37
LTB4R Q15722 2/20 0.37
F13A1 P00488 3/20 0.36
RPS6KB2 Q9UBS0 1/20 0.36
KDM4E B2RXH2 1/20 0.36
NPC1 O15118 1/20 0.36
CASP3 P42574 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8565291 0.89 LMNA (0.49) RXFP1ALDH1A1LMNAPRNPRECQL
SCHEMBL4197199 0.87 HPGD (0.70) RXFP1ALDH1A1LMNAPRNPRECQL
SCHEMBL9439542 0.85 HPGD (0.67) RXFP1ALDH1A1LMNAPRNPRECQL
SCHEMBL8982459 0.85 HPGD (0.45) RXFP1ALDH1A1LMNAPRNPRECQL
SCHEMBL21199747 0.85 POLB (0.46) RXFP1ALDH1A1LMNAPRNPRECQL
SCHEMBL8570240 0.83 HPGD (0.43) RXFP1ALDH1A1LMNAPRNPRECQL
SCHEMBL4195309 0.83 ALDH1A1 (0.46) RXFP1ALDH1A1LMNAPRNPRECQL
SCHEMBL5050275 0.82 HPGD (0.42) RXFP1ALDH1A1LMNAPRNPRECQL
SCHEMBL8564545 0.82 HPGD (0.45) RXFP1ALDH1A1LMNAPRNPRECQL
Hydrochloric Acid SCHEMBL5724631 0.81 HPGD (0.41) RXFP1ALDH1A1LMNAPRNPRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3000482-B1 DOUBLE-ACYLATED GLP-1 DERIVATIVES NOVO NORDISK AS (DK) 2021-04-21 EP disclosed
CN-104311657-B Double acylated GLP-1 derivatives 诺沃—诺迪斯克有限公司 2020-12-08 CN disclosed
CN-111560060-A Double acylated GLP-1 derivatives 诺沃—诺迪斯克有限公司 2020-08-21 CN disclosed
CN-104327182-B Double acylated GLP-1 derivatives 诺沃—诺迪斯克有限公司 2020-04-17 CN disclosed
US-9556250-B2 Double-acylated GLP-1 derivatives NOVO NORDISK A/S (DK) 2017-01-31 US disclosed
EP-3000482-A1 DOUBLE-ACYLATED GLP-1 DERIVATIVES Novo Nordisk A/S (DK) 2016-03-30 EP disclosed
EP-2513140-B1 DOUBLE-ACYLATED GLP-1 DERIVATIVES NOVO NORDISK AS (DK) 2015-11-04 EP disclosed
EP-2024390-B1 INSULIN DERIVATIVE NOVO NORDISK AS (DK) 2015-08-19 EP disclosed
EP-2024390-B1 INSULIN DERIVATIVE NOVO NORDISK AS (DK) 2015-08-19 EP disclosed
CN-104327182-A DOUBLE-ACYLATED GLP-1 DERIVATIVES NOVO NORDISK AS 2015-02-04 CN disclosed
US-20140179899-A1 DOUBLE-ACYLATED GLP-1 DERIVATIVES NOVO NORDISK A/S (DK) 2014-06-26 US disclosed
US-8648041-B2 Double-acylated GLP-1 derivatives NOVO NORDISK A/S (DK) 2014-02-11 US disclosed
EP-2513140-A1 DOUBLE-ACYLATED GLP-1 DERIVATIVES Novo Nordisk A/S (DK) 2012-10-24 EP disclosed
CN-102686607-A Double acylated GLP-1 derivatives NOVO NORDISK AS 2012-09-19 CN disclosed
WO-2011080103-A1 DOUBLE-ACYLATED GLP-1 DERIVATIVES NOVO NORDISK A/S (DK) 2011-07-07 WO disclosed
US-20110166321-A1 DOUBLE-ACYLATED GLP-1 DERIVATIVES NOVO NORDISK A/S (DK) 2011-07-07 US disclosed
US-20090105121-A1 Insulin Derivative NOVO NORDISK A/S (DK) 2009-04-23 US disclosed
US-20090105121-A1 Insulin Derivative NOVO NORDISK A/S (DK) 2009-04-23 US disclosed
US-20090105121-A1 Insulin Derivative NOVO NORDISK A/S (DK) 2009-04-23 US disclosed
WO-2007128815-A1 INSULIN DERIVATIVE NOVO NORDISK A/S (DK) 2007-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166321-A1 DOUBLE-ACYLATED GLP-1 DERIVATIVES GLP1R, IAPP, GCG RXFP1 51/4885ALDH1A1 2522/4885LMNA 3140/4885
US-20090105121-A1 Insulin Derivative INSR, IAPP, GPR119 RXFP1 351/4885ALDH1A1 4606/4885LMNA 2327/4885
US-20140179899-A1 DOUBLE-ACYLATED GLP-1 DERIVATIVES GLP1R, GCG, DPP7 RXFP1 65/4885ALDH1A1 936/4885LMNA 3895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.